|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM376977566 |
| 003 |
DE-627 |
| 005 |
20241101232316.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240902s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202408537
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1587.xml
|
| 035 |
|
|
|a (DE-627)NLM376977566
|
| 035 |
|
|
|a (NLM)39210629
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Maity, Debasis
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Glucose-Operated Widget (GLOW) for Closed-Loop Optogenetic Glycemic Control
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 01.11.2024
|
| 500 |
|
|
|a Date Revised 01.11.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2024 The Author(s). Advanced Materials published by Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Closed-loop control systems for precise control of therapeutic gene expression are promising candidates for personalized treatment of chronic ailments such as diabetes. Pancreatic iβ-cells are engineered with blue-light-inducible melanopsin to drive rapid insulin release by vesicular secretion from intracellular stores. In this work, a glucose-operated widget (GLOW) is designed as a component of a closed-loop control system for diabetes treatment by employing a probe that emits blue fluorescence in a glucose-concentration-dependent manner as a real-time glucose sensor to precisely control insulin release from these iβ-cells. As proof-of-concept of the complete control system, the probe is encapsulated together with iβ-cells in alginate-poly-(L-lysine) hydrogel-microbeads(400 µm in diameter and containing about 500 cells) called GLOWiβ (GLOW with iβ-cells), are subcutaneously implanted into type-1-diabetic (T1D) mice. Illumination by UV-A light at 390 nm results in glucose-concentration-dependent blue-light emission from the probe at 445 nm that in turn induces glucose-concentration-dependent insulin release from the iβ-cells in a fully reversible manner. Activation of the injected GLOWiβ at 390 nm for 15 min effectively restores normoglycemia within 60-120 min in a closed-loop manner in these diabetic mice. The system is robust, as normoglycemia is well maintained by daily activation for at least 7 days
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a beta cells
|
| 650 |
|
4 |
|a closed‐loop
|
| 650 |
|
4 |
|a insulin
|
| 650 |
|
4 |
|a synthetic biology
|
| 650 |
|
4 |
|a type‐1 diabetes
|
| 650 |
|
7 |
|a Glucose
|2 NLM
|
| 650 |
|
7 |
|a IY9XDZ35W2
|2 NLM
|
| 650 |
|
7 |
|a Insulin
|2 NLM
|
| 650 |
|
7 |
|a Hydrogels
|2 NLM
|
| 650 |
|
7 |
|a Blood Glucose
|2 NLM
|
| 650 |
|
7 |
|a Polylysine
|2 NLM
|
| 650 |
|
7 |
|a 25104-18-1
|2 NLM
|
| 650 |
|
7 |
|a Alginates
|2 NLM
|
| 700 |
1 |
|
|a Guha Ray, Preetam
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fussenegger, Martin
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 44 vom: 16. Nov., Seite e2408537
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:44
|g day:16
|g month:11
|g pages:e2408537
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202408537
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 44
|b 16
|c 11
|h e2408537
|